Publication date: May 20, 2025
AL001 is designed to favorably distribute lithium in the brain resulting in lower exposure of other body organs and an improved safety profile compared to currently marketed lithium salts. Since conventional lithium salts are eliminated relatively quickly, multiple administrations throughout the day are required to safely reach therapeutic plasma concentrations. This MTD is designed to be unlikely to require TDM while providing lithium at a relatively modest but effective dose. Lithium, renowned for its efficacy as a first-line therapy for manic episodes and maintenance in BD, has long been underutilized due to the complexities of TDM. More information, including potential risk factors, that could affect Alzamends business and financial results are included in Alzamends filings with the U. S. Securities and Exchange Commission. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. AL001 has the potential to transform the treatment landscape for over 43 million Americans affected by Alzheimers, BD, MDD and PTSD.
| Concepts | Keywords |
|---|---|
| Alzheimers | Al001 |
| Massachusetts | Alzamend |
| Nervous | Alzheimers |
| Pharmacokinetics | Bd |
| Tesla | Brain |
| Clinical | |
| Lithium | |
| Looking | |
| Marketed | |
| Patient | |
| Potential | |
| Salts | |
| Statements | |
| Therapeutic | |
| Treatment |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Lithium carbonate |
| disease | MESH | bipolar disorder |
| disease | MESH | major depressive disorder |
| disease | MESH | post-traumatic stress disorder |
| drug | DRUGBANK | Nonoxynol-9 |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | manic episodes |
| drug | DRUGBANK | Proline |
| pathway | REACTOME | Release |
| drug | DRUGBANK | Coenzyme M |